Edit |   |
---|---|
Antigenic Specificity | CD64, Mouse |
Clone | REA286 |
Host Species | Recombinant Human |
Reactive Species | mouse |
Isotype | IgG1 |
Format | allophycocyanin (APC) conjugate |
Size | 30 µg in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD64 Antibody, anti-mouse, APC, REAfinity™. Clone REA286 recognizes the CD64 antigen, a 72 kDa integral membrane glycoprotein also known as high affinity immunoglobulin gamma Fc receptor I (FcγRI). Structurally CD64 is composed of a signal peptide that allows its transport to the surface of a cell, three extracellular immunoglobulin domains of the C2-type that it uses to bind antibody, a hydrophobic transmembrane domain, and a short cytoplasmic tail. CD64 is constitutively expressed on macrophages, monocytes, dendritic cells, and mast cells. Treatment with cytokines like IFN-γ and G-CSF induces CD64 upregulation. CD64 binds monomeric IgG-type antibodies with high affinity and mediates endocytosis, phagocytosis, antibody-dependent cellular toxicity, cytokine release, and superoxide generation. | Additional information: Clone REA286 displays negligible binding to Fc receptors. | |
Immunogen | n/a |
Other Names | FCGR1, FcgammaRI, IGGHAFC, FcR I, FcγRI |
Gene, Accession # | Gene ID: 14129 |
Catalog # | 130-126-950 |
Price | $91 |
Order / More Info | CD64, Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Tan, P. S. et al. (2003) Unique monoclonal antibodies define expression of FcgRI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol 170: 2549-2556. | Ioan-Facsinay, A. et al. (2002) FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16 (3): 391-402. | Nimmerjahn, F. et al. (2006) Fcgamma receptors: old friends and new family members. Immunity 24 (1): 19-28. |